公开(公告)号：US07320675B2

公开(公告)日：2008-01-22

申请号：US10645823

申请日：2003-08-21

申请人： Joseph M. Pastore ,  Julio C. Spinelli ,  Helen L. Reeve ,  Jeffrey Ross ,  Rodney W. Salo ,  Allan Shuros

发明人： Joseph M. Pastore ,  Julio C. Spinelli ,  Helen L. Reeve ,  Jeffrey Ross ,  Rodney W. Salo ,  Allan Shuros

IPC分类号： A61M31/00

CPC分类号： A61M5/1723 ,  A61B5/0031 ,  A61B5/1107 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/4839 ,  A61M5/14244 ,  A61M5/14276 ,  A61M2205/3523 ,  A61N1/3627

摘要： A drug delivery system detects a cardiac condition indicative of a need for increasing a cardiac metabolic level and, in response, releases a drug into tissue or blood to shift a source of metabolically synthesized energy fueling cardiac contraction from fatty acid to glucose. One example of such a system includes an implantable device detecting an ischemia and a transdermal drug delivery device delivering a drug when an ischemic condition is detected. Another example of such a system includes one or more implantable devices detecting a predefined change in cardiac metabolic level and delivering a drug when the change is detected. Such systems are applied to treat, for example, patients suffering ischemia and/or heart failure and patients having suffered myocardial infarction.

公开(公告)号：US08016783B2

公开(公告)日：2011-09-13

申请号：US11998969

申请日：2007-12-03

申请人： Joseph M. Pastore ,  Julio C. Spinelli ,  Helen L. Reeve ,  Jeffrey Ross ,  Rodney W. Salo ,  Allan Shuros

发明人： Joseph M. Pastore ,  Julio C. Spinelli ,  Helen L. Reeve ,  Jeffrey Ross ,  Rodney W. Salo ,  Allan Shuros

IPC分类号： A61M31/00

CPC分类号： A61M5/1723 ,  A61B5/0031 ,  A61B5/1107 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/4839 ,  A61M5/14244 ,  A61M5/14276 ,  A61M2205/3523 ,  A61N1/3627

摘要： A drug delivery system detects a cardiac condition indicative of a need for increasing a cardiac metabolic level and, in response, releases a drug into tissue or blood to shift a source of metabolically synthesized energy fueling cardiac contraction from fatty acid to glucose. One example of such a system includes an implantable device detecting an ischemia and a transdermal drug delivery device delivering a drug when an ischemic condition is detected. Another example of such a system includes one or more implantable devices detecting a predefined change in cardiac metabolic level and delivering a drug when the change is detected. Such systems are applied to treat, for example, patients suffering ischemia and/or heart failure and patients having suffered myocardial infarction.

摘要翻译： 药物递送系统检测指示需要增加心脏代谢水平的心脏状况，并且作为响应将药物释放到组织或血液中以将促进心脏收缩的代谢合成能量的来源从脂肪酸转移到葡萄糖。 这种系统的一个实例包括检测缺血的可植入装置和当检测到缺血状况时递送药物的透皮药物递送装置。 这种系统的另一个例子包括一个或多个可植入装置，用于检测心脏代谢水平的预定变化并在检测到变化时递送药物。 这种系统被应用于治疗例如患有缺血和/或心力衰竭的患者和患有心肌梗塞的患者。

公开(公告)号：US20100274306A1

公开(公告)日：2010-10-28

申请号：US12830534

申请日：2010-07-06

申请人： Joseph M. Pastore ,  Jeffrey Ross ,  Tamara Colette Baynham ,  Rodney W. Salo ,  Andrew P. Kramer ,  Julio C. Spinelli

发明人： Joseph M. Pastore ,  Jeffrey Ross ,  Tamara Colette Baynham ,  Rodney W. Salo ,  Andrew P. Kramer ,  Julio C. Spinelli

IPC分类号： A61M37/00 ,  A61N1/00

CPC分类号： A61N1/3627 ,  A61K48/0083 ,  A61N1/36514

摘要： A gene regulatory system detects ischemia events and is capable of delivering a biologic therapy in response to the detection of an ischemic event or the reception of a command. The biologic therapy protects the heart from ischemic damage by regulating the expression of an exogenously introduced gene product. In one embodiment, the gene regulatory system includes an implantable system that emits at least one gene regulatory signal in response to the detection of the ischemic event or the reception of the command. The gene regulatory signal directly or indirectly regulates gene expression of the gene product.

摘要翻译： 基因调控系统检测缺血事件，并且能够响应于缺血事件的检测或命令的接收而递送生物疗法。 生物治疗通过调节外源基因产物的表达来保护心脏免于缺血性损伤。 在一个实施方案中，基因调控系统包括可植入系统，其可以响应于缺血事件的检测或命令的接收而发射至少一个基因调节信号。 基因调控信号直接或间接调控基因产物的基因表达。

公开(公告)号：US20100145401A1

公开(公告)日：2010-06-10

申请号：US12703382

申请日：2010-02-10

申请人： Joseph M. Pastore ,  Tamara Colette Baynham ,  Andrew P. Kramer ,  Julio C. Spinelli ,  Jeffrey Ross ,  Rodney W. Salo

发明人： Joseph M. Pastore ,  Tamara Colette Baynham ,  Andrew P. Kramer ,  Julio C. Spinelli ,  Jeffrey Ross ,  Rodney W. Salo

IPC分类号： A61N1/362

CPC分类号： A61N1/36114 ,  A61N1/3627 ,  A61N1/37211 ,  A61N1/3956

摘要： Various system embodiments comprise a neural stimulator, a pulse generator, and a controller. The neural stimulator is adapted to generate a neural stimulation signal. The pulse generator is adapted to generate a pacing signal to provide myocardium pacing. The controller is adapted to control the neural stimulator and the pulse generator to provide a cardioprotective conditioning therapy. The conditioning therapy includes neural stimulation to elicit a parasympathetic response and myocardium pacing. Other aspects and embodiments are provided herein.

摘要翻译： 各种系统实施例包括神经刺激器，脉冲发生器和控制器。 神经刺激器适于产生神经刺激信号。 脉冲发生器适用于产生起搏信号以提供心肌起搏。 控制器适用于控制神经刺激器和脉冲发生器以提供心脏保护性调理疗法。 调理疗法包括神经刺激以引发副交感神经反应和心肌起搏。 本文提供了其它方面和实施例。

公开(公告)号：US20090143835A1

公开(公告)日：2009-06-04

申请号：US12322382

申请日：2009-02-02

申请人： Joseph M. Pastore ,  Andrew P. Kramer ,  Julio C. Spinelli ,  Rodney W. Salo ,  Tamara Colette Baynham ,  Jeffrey Ross ,  Frits W. Prinzen ,  Ward Y. R. Vanagt ,  Richard N. Cornelussen

发明人： Joseph M. Pastore ,  Andrew P. Kramer ,  Julio C. Spinelli ,  Rodney W. Salo ,  Tamara Colette Baynham ,  Jeffrey Ross ,  Frits W. Prinzen ,  Ward Y. R. Vanagt ,  Richard N. Cornelussen

IPC分类号： A61N1/365

CPC分类号： A61N1/056 ,  A61N1/3627 ,  A61N1/36557 ,  A61N1/37205 ,  A61N1/3787 ,  A61N2001/0585

摘要： An implantable cardiac protection pacing system delivers pacing pulses to protect the heart from injuries associated with ischemia and myocardial infarction. The system includes an implantable pulse generator (PG) that delivers the pacing pulses and a coronary stent electrically connected to the implantable PG to function as a pacing electrode through which the pacing pulses are delivered. In one embodiment, an intravascular lead provides the electrical connection between the coronary stent and the implantable PG to allow the implantable PG to be implanted in the femoral region. In another embodiment, the coronary stent and the implantable PG are integrated into an intravascular pulse generator-stent.

摘要翻译： 可植入心脏保护起搏系统提供起搏脉冲，以保护心脏免受与缺血和心肌梗塞相关的损伤。 该系统包括输送起搏脉冲的可植入脉冲发生器（PG）和电连接到可植入PG的冠状动脉支架，起到起搏电极的作用，起搏电极通过该起搏电极被输送。 在一个实施例中，血管内引线提供冠状支架和可植入PG之间的电连接，以允许将可植入PG植入股骨区域。 在另一个实施例中，冠状动脉支架和可植入PG集成到血管内脉冲发生器 - 支架中。

公开(公告)号：US08731677B2

公开(公告)日：2014-05-20

申请号：US12703382

申请日：2010-02-10

申请人： Joseph M. Pastore ,  Tamara Colette Baynham ,  Andrew P. Kramer ,  Julio C. Spinelli ,  Jeffrey Ross ,  Rodney W. Salo

发明人： Joseph M. Pastore ,  Tamara Colette Baynham ,  Andrew P. Kramer ,  Julio C. Spinelli ,  Jeffrey Ross ,  Rodney W. Salo

IPC分类号： A61N1/00

CPC分类号： A61N1/36114 ,  A61N1/3627 ,  A61N1/37211 ,  A61N1/3956

摘要： Various system embodiments comprise a neural stimulator, a pulse generator, and a controller. The neural stimulator is adapted to generate a neural stimulation signal. The pulse generator is adapted to generate a pacing signal to provide myocardium pacing. The controller is adapted to control the neural stimulator and the pulse generator to provide a cardioprotective conditioning therapy. The conditioning therapy includes neural stimulation to elicit a parasympathetic response and myocardium pacing. Other aspects and embodiments are provided herein.

摘要翻译： 各种系统实施例包括神经刺激器，脉冲发生器和控制器。 神经刺激器适于产生神经刺激信号。 脉冲发生器适于产生起搏信号以提供心肌起搏。 控制器适用于控制神经刺激器和脉冲发生器以提供心脏保护性调理疗法。 调理疗法包括神经刺激以引发副交感神经反应和心肌起搏。 本文提供了其它方面和实施例。

公开(公告)号：US07774057B2

公开(公告)日：2010-08-10

申请号：US11220397

申请日：2005-09-06

申请人： Joseph M. Pastore ,  Jeffrey Ross ,  Tamara Colette Baynham ,  Rodney W. Salo ,  Andrew P. Kramer ,  Julio C. Spinelli

发明人： Joseph M. Pastore ,  Jeffrey Ross ,  Tamara Colette Baynham ,  Rodney W. Salo ,  Andrew P. Kramer ,  Julio C. Spinelli

IPC分类号： A61N1/08

CPC分类号： A61N1/3627 ,  A61K48/0083 ,  A61N1/36514

摘要： A gene regulatory system detects ischemia events and is capable of delivering a biologic therapy in response to the detection of an ischemic event or the reception of a command. The biologic therapy protects the heart from ischemic damage by regulating the expression of an exogenously introduced gene product. In one embodiment, the gene regulatory system includes an implantable system that emits at least one gene regulatory signal in response to the detection of the ischemic event or the reception of the command. The gene regulatory signal directly or indirectly regulates gene expression of the gene product.

摘要翻译： 基因调控系统检测缺血事件，并且能够响应于缺血事件的检测或命令的接收而递送生物疗法。 生物治疗通过调节外源基因产物的表达来保护心脏免于缺血性损伤。 在一个实施方案中，基因调控系统包括可植入系统，其可以响应于缺血事件的检测或命令的接收而发射至少一个基因调节信号。 基因调控信号直接或间接调控基因产物的基因表达。

公开(公告)号：US07689286B2

公开(公告)日：2010-03-30

申请号：US11381211

申请日：2006-05-02

申请人： Joseph M. Pastore ,  Tamara Colette Baynham ,  Andrew P. Kramer ,  Julio C. Spinelli ,  Jeffrey Ross ,  Rodney W. Salo

发明人： Joseph M. Pastore ,  Tamara Colette Baynham ,  Andrew P. Kramer ,  Julio C. Spinelli ,  Jeffrey Ross ,  Rodney W. Salo

IPC分类号： A61N1/362

CPC分类号： A61N1/36114 ,  A61N1/3627 ,  A61N1/37211 ,  A61N1/3956

摘要： Various system embodiments comprise a neural stimulator, a pulse generator, and a controller. The neural stimulator is adapted to generate a neural stimulation signal. The pulse generator is adapted to generate a pacing signal to provide myocardium pacing. The controller is adapted to control the neural stimulator and the pulse generator to provide a cardioprotective conditioning therapy. The conditioning therapy includes neural stimulation to elicit a parasympathetic response and myocardium pacing. Other aspects and embodiments are provided herein.

摘要翻译： 各种系统实施例包括神经刺激器，脉冲发生器和控制器。 神经刺激器适于产生神经刺激信号。 脉冲发生器适于产生起搏信号以提供心肌起搏。 控制器适用于控制神经刺激器和脉冲发生器以提供心脏保护性调理疗法。 调理疗法包括神经刺激以引发副交感神经反应和心肌起搏。 本文提供了其它方面和实施例。

公开(公告)号：US08538520B2

公开(公告)日：2013-09-17

申请号：US12830534

申请日：2010-07-06

申请人： Joseph M. Pastore ,  Jeffrey Ross ,  Tamara Colette Baynham ,  Rodney W. Salo ,  Andrew P. Kramer ,  Julio C. Spinelli

发明人： Joseph M. Pastore ,  Jeffrey Ross ,  Tamara Colette Baynham ,  Rodney W. Salo ,  Andrew P. Kramer ,  Julio C. Spinelli

IPC分类号： A61N1/36

CPC分类号： A61N1/3627 ,  A61K48/0083 ,  A61N1/36514

摘要： A gene regulatory system detects ischemia events and is capable of delivering a biologic therapy in response to the detection of an ischemic event or the reception of a command. The biologic therapy protects the heart from ischemic damage by regulating the expression of an exogenously introduced gene product. In one embodiment, the gene regulatory system includes an implantable system that emits at least one gene regulatory signal in response to the detection of the ischemic event or the reception of the command. The gene regulatory signal directly or indirectly regulates gene expression of the gene product.

摘要翻译： 基因调控系统检测缺血事件，并且能够响应于缺血事件的检测或命令的接收而递送生物疗法。 生物治疗通过调节外源基因产物的表达来保护心脏免于缺血性损伤。 在一个实施方案中，基因调控系统包括可植入系统，其可以响应于缺血事件的检测或命令的接收而发射至少一个基因调节信号。 基因调控信号直接或间接调控基因产物的基因表达。

公开(公告)号：US08311630B2

公开(公告)日：2012-11-13

申请号：US13229948

申请日：2011-09-12

申请人： Joseph M. Pastore ,  Rodney W. Salo ,  Julio C. Spinelli ,  Allan C. Shuros ,  Andres Belalcazar

发明人： Joseph M. Pastore ,  Rodney W. Salo ,  Julio C. Spinelli ,  Allan C. Shuros ,  Andres Belalcazar

IPC分类号： A61N1/365

CPC分类号： A61N1/3627 ,  A61N1/36521 ,  A61N1/36535 ,  A61N1/36542 ,  A61N1/36564 ,  A61N1/3688

摘要： An implantable pacing device for delivering ventricular pacing may be configured to intermittently reduce the AVD interval for beneficial effect in patients with compromised ventricular function (e.g., HF patients and post-MI patients). The AVD interval may be reduced in an AVD reduction mode, by shortening the AVD in an atrial triggered ventricular pacing mode or by switching to a non-atrial triggered ventricular pacing mode (e.g., VVI) and delivering paces at a rate above the intrinsic rate. The physiological effects of AVD reduction may be either positive or negative on cardiac output, depending upon the individual patient.

摘要翻译： 用于输送心室起搏的可植入起搏装置可以被配置为间歇地减小AVD间隔，以在患有心室功能受损的患者（例如，HF患者和MI后患者）中产生有益效果。 通过在心房触发的心室起搏模式中缩短AVD或者通过切换到非心房触发的心室起搏模式（例如，VVI）并以高于内在速率的速率递送步进，AVD间期可以减小AVD减小模式 。 取决于个体患者，AVD减少的生理作用可能是心输出量的正或负。